Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art.

Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. Vaccine. 2015 Aug 10; Authors: Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK Abstract Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil(®) and Cervarix(®) vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vagina cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil(®) vaccine also offer additional protection against anal cancer precursors. However, high costs of HPV vaccines and the logistics of delivering a three-dose schedule over 6 months are challenging in countries with limited resources. Several studies have demonstrated non-inferiority in antibody response between adolescents (9-15 years old) who received two doses (6 months apart) and women (>15 years old) who received the standard three-dose schedule. These studies provided evidence for the World Health Organization and European Medical Association to revise its recommendation to give two instead of three doses of HPV vaccine to adolescents below 15 ...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research